Penicillins and Cephalosporins

1. Front Matter

   Pages i-xiv

   PDF

2. The Beta Lactam Antibiotics — Penicillins and Cephalosporins

   • G. T. Stewart

   Pages 1-5

3. Clinical Relevance of Ampicillin/Cloxacillin for IV Use

   • C. Regamey, L. Barrelet, F. A. Waldvogel

   Pages 7-12

4. Experiences with Amoxicillin in Full-Term and Pre-Term Neonates

   • L. Weingärtner, U. Sitka, R. Patsch

   Pages 13-18

5. Comparative Activity of Amoxycillin, Ampicillin and Benzylpenicillin Against Streptococci Causing Bacterial Endocarditis

   • M. J. Basker, C. E. Moon

   Pages 19-24

6. A Multicentre Study of Talampicillin and Ampicillin in General Practice

   • O. P. W. Robinson

   Pages 25-30

7. Pharmacological and Clinical Studies with Talampicillin, an Ester of Ampicillin

   • P. J. Wilkinson, A. L. Thomas, D. S. Reeves, J. Symonds

   Pages 31-36

8. Pharmacokinetic Studies of Serum Levels and Urinary Excretion of Ticarcillin after Intravenous and Intramuscular Administration to Patients with Normal and Abnormal Renal Function

   • M. J. Parry, H. C. Neu

   Pages 37-43

9. The Use of Ticarcillin in the Treatment of Acute Urinary Tract Infections

   • H. David Short, Layne O. Gentry

   Pages 45-49

10. Microbiology of Carfecillin, The α-Phenyl Ester of Carbenicillin

    • M. J. Basker, R. Sutherland

    Pages 51-55

11. Chemotherapeutic Activity of Carfecillin, the α-Phenyl Ester of Carbenicillin, in the Treatment of Experimental Mouse Infections

    • K. R. Comber, G. Valler

    Pages 57-62

12. Pharmacological and Clinical Studies with Carfecillin, an Orally Administered Ester of Carbenicillin

    • P. J. Wilkinson, D. S. Reeves, R. Wise

    Pages 63-69

13. Determination of Indanyl Carbenicillin in Urine with Blood

    • M. Pina de Carvalho, A. Matos Ferreira

    Pages 71-73

14. In Vitro Activity and Clinical Use of Indanyl Carbenicillin

    • G. Fontana, M. Laudi

    Pages 75-82

15. Clinical Experience with Geopen (Carbenicillin)

    • Ž. Ivić

    Pages 83-85

16. Indanyl Carbenicillin and Urinary Infections

    • R. Pedrotti, V. Forte

    Pages 87-92

17. Oral Treatment with Carindacillin in Patients Suffering from Urinary Tract Infections

    • L. Cioni, N. Pilone, L. Moriconi

    Pages 93-97

18. Carindacillin in the Therapy of Urinary Tract Infections

    • T. Germinale, C. Giglio

    Pages 99-101

19. Urinary Levels of Carindacillin in the Pediatric Age

    • A. Ferro, G. Ceccarelli, G. R. Burgio

    Pages 103-107

20. Clinical Pharmacological Studies with Bacampicillin

    • L. Magni, B. Sjöberg, J. Sjövall, J. Wessman

    Pages 109-114

The International Society o~ Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extepsion of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

• cancer
• chemotherapy
• kinetics
• pharmacokinetics
• research
• resistance
• toxicity

• The London Hospital Medical College, London, UK

  J. D. Williams

• East Birmingham Hospital, Birmingham, UK

  A. M. Geddes

Policies and ethics